Schizophrenia Research Today is a free monthly online journal that collates and summarizes the latest research about Schizophrenia, including details on paranoia, symptoms, treatment, depression, medication.

Volume 1 (2004), Issue 2 (October)

1. Does urbanicity shift the population expression of psychosis?
   J Psychiatr Res, 38(6): 613-8. [Abstract] [Full-text]
2. Secondary verbal memory: a potential endophenotype of schizophrenia.
   J Psychiatr Res, 38(6): 601-12. [Abstract] [Full-text]
3. Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia.
   J Psychiatr Res, 38(6): 591-9. [Abstract] [Full-text]
4. Impaired emotional learning and reduced amygdala size in schizophrenia: a 3-month follow-up.
   Schizophr Res, 71(2): 493-503. [Abstract] [Full-text]
5. Paracontrast and metacontrast in schizophrenia: clarifying the mechanism for visual masking deficits.
   Schizophr Res, 71(2): 485-92. [Abstract] [Full-text]
6. Thalamus size and outcome in schizophrenia.
   Schizophr Res, 71(2): 473-84. [Abstract] [Full-text]
7. Social cognitive bias and neurocognitive deficit in paranoid symptoms: evidence for an interaction effect and changes during treatment.
   Schizophr Res, 71(2): 463-71. [Abstract] [Full-text]
8. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.
   Schizophr Res, 71(2): 445-62. [Abstract] [Full-text]
9. Use of antipsychotic medications among HIV-infected individuals with schizophrenia.
   Schizophr Res, 71(2): 435-44. [Abstract] [Full-text]
10. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.
    Schizophr Res, 71(2): 427-34. [Abstract] [Full-text]
11. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder.
    Schizophr Res, 71(2): 405-16. [Abstract] [Full-text]
12. An electrophysiological (ERP) component, the recognition potential, in the assessment of brain semantic networks in patients with schizophrenia.
    Schizophr Res, 71(2): 393-404. [Abstract] [Full-text]
13. Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects.
    Schizophr Res, 71(2): 383-92. [Abstract] [Full-text]
14. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients.
    Schizophr Res, 71(2): 377-82. [Abstract] [Full-text]
15. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.
    Schizophr Res, 71(2): 371-5. [Abstract] [Full-text]
16. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder.
    Schizophr Res, 71(2): 361-70. [Abstract] [Full-text]
17. Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia.
    Schizophr Res, 71(2): 353-60. [Abstract] [Full-text]
18. Verbal memory processes in schizophrenia patients and biological relatives of schizophrenia patients: intact implicit memory, impaired explicit recollection.
    Schizophr Res, 71(2): 339-48. [Abstract] [Full-text]
19. Self-awareness of cognitive functioning in schizophrenia.
    Schizophr Res, 71(2): 331-8. [Abstract] [Full-text]
20. Neuropsychological correlates of symptom profiles in first episode schizophrenia.
    Schizophr Res, 71(2): 323-30. [Abstract] [Full-text]
21. Heterogeneity of schizophrenia: a study of individual neuropsychological profiles.
    Schizophr Res, 71(2): 307-21. [Abstract] [Full-text]
22. Measuring cognitive insight in middle-aged and older patients with psychotic disorders.
    Schizophr Res, 71(2): 297-305. [Abstract] [Full-text]
23. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis.
    Schizophr Res, 71(2): 285-95. [Abstract] [Full-text]
24. A brief cognitive assessment for use with schizophrenia patients in community clinics.
    Schizophr Res, 71(2): 273-83. [Abstract] [Full-text]
25. Decreased nonlinear complexity and chaos during sleep in first episode schizophrenia: a preliminary report.
    Schizophr Res, 71(2): 263-72. [Abstract] [Full-text]
26. Cingulate gyrus volume and metabolism in the schizophrenia spectrum.
    Schizophr Res, 71(2): 249-62. [Abstract] [Full-text]
27. Effects of D-cycloserine on negative symptoms in schizophrenia.
    Schizophr Res, 71(2): 239-48. [Abstract] [Full-text]
28. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'.
    Schizophr Res, 71(2): 227-37. [Abstract] [Full-text]
29. The persistence of developmental markers in childhood and adolescence and risk for schizophrenic psychoses in adult life. A 34-year follow-up of the Northern Finland 1966 birth cohort.
    Schizophr Res, 71(2): 213-25. [Abstract] [Full-text]
30. Atypical antipsychotics and glucose dysregulation: a systematic review.
    Schizophr Res, 71(2): 195-212. [Abstract] [Full-text]
31. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia.
    Trends Neurosci, 27(11): 683-90. [Abstract] [Full-text]
32. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics.
    Synapse, 54(3): 147-55. [Abstract] [Full-text]
33. The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia.
    Exp Brain Res, 159(1): 99-107. [Abstract] [Full-text]
34. Attentional facilitation of response is impaired for antisaccades but not for saccades in patients with schizophrenia: implications for cortical dysfunction.
    Exp Brain Res, 159(1): 47-54. [Abstract] [Full-text]
35. Reduced perception of pain in schizophrenia: its relevance to the clinical diagnosis of compartment syndrome.
    Injury, 35(11): 1192-3. [Abstract] [Full-text]
36. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia.
    Hum Mol Genet, 13(21): 2699-708. [Abstract] [Full-text]
37. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Br J Clin Pharmacol, 58: 50-7. [Abstract] [Full-text]
38. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.
    Neuropsychopharmacology, 29(11): 2108-14. [Abstract] [Full-text]
39. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens.
    Neuropsychopharmacology, 29(11): 2052-64. [Abstract] [Full-text]
40. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse.
    Neurosci Lett, 371(1): 79-83. [Abstract] [Full-text]
41. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale?
    Behav Res Ther, 42(12): 1377-401. [Abstract] [Full-text]
42. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
    Pharmacoepidemiol Drug Saf, 13(11): 811-6. [Abstract] [Full-text]
43. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.
    Eur Psychiatry, 19(7): 415-22. [Abstract] [Full-text]
44. Family disruption, economic hardship and psychological distress in schizophrenia: can they be measured?
    Eur Psychiatry, 19(7): 408-14. [Abstract] [Full-text]
45. A study of the family burden of 150 family members of schizophrenic patients.
    Eur Psychiatry, 19(7): 395-401. [Abstract] [Full-text]
46. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
    J Psychiatr Res, 39(1): 109-15. [Abstract] [Full-text]
47. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    J Psychiatr Res, 39(1): 101-8. [Abstract] [Full-text]
48. Proton magnetic resonance spectroscopy (1H-MRS) of hippocampus, basal ganglia, and vermis of cerebellum in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome).
    J Psychiatr Res, 39(1): 29-34. [Abstract] [Full-text]
49. Replication of 1q42 linkage in Finnish schizophrenia pedigrees.
    Mol Psychiatry, 9(11): 1037-41. [Abstract] [Full-text]
50. Childhood videotaped social and neuromotor precursors of schizophrenia: a prospective investigation.
    Am J Psychiatry, 161(11): 2021-7. [Abstract] [Full-text]

© 2004-2010 Schizophrenia Research Today. All Rights Reserved.